Launch of Contracted COVID-19 PCR Testing
First written in FY2020. 8 of 12 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2023-Q2.
1 other company's latest entry also says "Restated".
- FY2023-Q2RestatedAnnual report
「During the six-month period ended the second quarter, revenue from the diagnostic analysis business operated by 株式会社ジェネティックラボ, including revenue from contracted COVID-19 PCR testing, declined by the corresponding amount following the transfer of all shares in the company in January 2022.」
It reconfirms that, following the transfer of all shares in ジェネティックラボ, revenue from the diagnostic analysis business, including contracted PCR testing, declined from the consolidated results. - FY2023-Q1Decline in Contract Testing Revenue Following the TransferAnnual report
「Following the transfer of all shares in 株式会社ジェネティックラボ in January 2022, revenue from the diagnostic analysis business operated by the company, including revenue from contracted COVID-19 PCR testing, declined by the corresponding amount.」
Following the transfer of all shares in ジェネティックラボ, revenue from the diagnostic analysis business operated by the company, including contracted PCR testing, declined from the consolidated results. - FY2022-Q3Decline in PCR Testing VolumeAnnual report
「Although the number of tests remained high through the second quarter of the consolidated fiscal period, both the number of infections and the number of tests declined during the third quarter, and the impact on performance became limited.」
Contracted PCR testing remained at a high level through the second quarter, but the number of infections and tests declined during the third quarter, limiting its contribution to performance. - FY2022-Q2AdvancedAnnual report
「During the six-month period ended the second quarter, the number of contracted COVID-19 tests significantly exceeded expectations as a result of the spread of COVID-19 infections.」
The number of contracted PCR tests significantly exceeded expectations, contributing to the upward revision of the full-year earnings forecast. - FY2022-Q2AdvancedAnnual report
「To handle the increase in testing, the Company expanded the equipment required for testing and began providing contracted variant screening tests, which involve additional testing of specimens that tested positive in the COVID-19 PCR testing currently being conducted.」
For PCR testing, the Company expanded its testing equipment and began providing contracted variant screening tests for positive specimens. - FY2022-Q1AdvancedAnnual report
「In the drug discovery support business, the Company had been providing contracted SARS-CoV-2 PCR testing services in Hokkaido. To handle the increase in testing, it expanded the equipment required for testing and began providing contracted variant screening tests, which involve additional testing of specimens that tested positive in the COVID-19 PCR testing currently being conducted.」
For PCR testing, the Company expanded its testing equipment and began providing contracted variant screening tests for positive specimens. The sharp increase in testing in Hokkaido resulted in a 255.7% year-on-year increase in revenue in the drug discovery support business. - FY2021AdvancedAnnual report
「The contracted COVID-19 testing services, including PCR testing, launched in April 2020 saw a significant increase in the number of contracted tests from summer 2020 onward as testing for COVID-19 expanded.」
The number of contracted PCR tests increased significantly from summer 2020 onward, contributing to a ¥787.892 million increase in revenue in the drug discovery support business. - FY2021-Q3AdvancedAnnual report
「The Company also began providing contracted COVID-19 testing services, including PCR testing. As testing increased following a rapid resurgence of COVID-19 infections in Hokkaido, the number of contracted tests rose significantly during the third quarter.」
The number of contracted PCR tests increased significantly during the third quarter in response to the rise in testing following the resurgence of infections in Hokkaido. - FY2021-Q3AdvancedAnnual report
「In the drug discovery support business, as COVID-19 infections spread, 株式会社ジェネティックラボ began providing contracted COVID-19 testing services, including PCR testing, for Sapporo City and Hokkaido to support the increase in testing. It also proceeded with expanding the equipment required for testing to handle the increased number of tests.」
For contracted PCR testing services, the Company proceeded with expanding equipment to handle the increase in testing in addition to contracts from Sapporo City and Hokkaido, aiming to expand its service capacity. - FY2021-Q2AdvancedAnnual report
「Although the Company began providing contracted COVID-19 testing services, including PCR testing, the number of contracted tests increased during the second quarter compared with the first quarter.」
It states that the number of contracted PCR tests increased in the second quarter compared with the first quarter, expanding the service track record. - FY2021-Q1AdvancedAnnual report
「In the drug discovery support business, amid the spread of COVID-19, 株式会社ジェネティックラボ began accepting contract COVID-19 testing, including PCR testing, from Sapporo City and Hokkaido to support the increase in testing volumes.」
For the contracted PCR testing services launched in the previous fiscal year, the customer base and order base expanded, with services beginning under contracts from Sapporo City and Hokkaido. - FY2020First statedAnnual report
「In addition, as the spread of COVID-19 increased, 株式会社ジェネティックラボ established the necessary structure to meet social demand and began accepting contract COVID-19 testing, including PCR testing, in March 2020.」
ジェネティックラボ established the necessary systems and began providing contracted COVID-19 PCR testing services in March 2020.